(Q34313459)

1 August 2017

1 reference

title

Low molecular weight heparin(s). (English)

1 reference

1 August 2017

1 reference

Barrowcliffe TW

1

1 reference

PubMed ID

7786769

1 August 2017

language of work or name

English

0 references

publication date

1 May 1995

1 reference

British Journal of Haematology

1 August 2017

1 reference

1 August 2017

90

1 reference

1 August 2017

1

1 reference

1 August 2017

1-7

1 reference

The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides

1 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Anticoagulant activities of heparin and fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Pharmacokinetics of heparin and low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Antithrombotic effects of heparin oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

The effect of low molecular weight heparin on experimental thrombosis and haemostasis--the influence of production method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Further characterization of the antithrombin-binding sequence in heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB03373.X

10.1111/J.1365-2141.1995.TB03373.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

7786769